Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granisetron hydrochloride; and preparation products, such as cardiovascular preparations torsemide tablets and non-steroidal anti-inflammatory preparations ibuprofen granules, and other preparations. In addition, it offers non-anti-inflammatory APIs, cardiovascular, anti-tumor, and anticholinergic APIs and intermediates; antipyretic and analgesic, cardiovascular and anti-infective preparations; and chemicals and formulations. Hubei Biocause Heilen Pharmaceutical Co., Ltd. was founded in 1995 and is based in Jingmen, China.
Headquarters: Jingmen · Employees: 952 · Website: https://www.biocause.com
Guangdong Zhengju Transmission Technology Co., Ltd. (301211.SZ) is a publicly traded company in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Competitors of Guangdong Zhengju Transmission Technology Co., Ltd. (301211.SZ) tracked by Macroplane include ALLIENT INC (ALNT), CKD Corporation (6407.T), DANA Inc (DAN), Han's Laser Technology Industry Group Co., Ltd. (002008.SZ), Harmonic Drive Systems Inc. (6324.T), Hirata Corporation (6481.T), HIWIN Technologies Corp. (2049.TW), INTERNATIONAL PAPER CO /NEW/ (IP), and 4 more.
Search companies · Macro trends · Industries · Product categories · Baskets